Effect of Rebamipide Combined with Routine Quadruple Therapy on Gastrointestinal Hormones and Pepsinogen in Patients with Chronic Atrophic Gastritis Infected by Hp
Objective To explore the therapeutic effect of ribavirin combined with conventional quadruple therapy in patients with chronic atrophic gastritis (CAG) caused by Helicobacter Pylori (Hp) infection. Methods A total of 70 patients with CAG caused by Hp infection admitted to the hospital from May 2021 to June 2023 were selected as the research objects,and they were divided into a control group and an observation group according to the random number table method. The control group (n=35) received conventional quadruple therapy,while the observation group (n=35) received a combination of remifentanil and remifentanil on the basis of the control group. Both groups received continuous treatment for 2 weeks. Compare the levels of gastrointestinal hormones,pepsinogen,occurrence of adverse reactions,and Hp eradication rates between two groups. Results After treatment,the level of gastrin in the observation group were lower than those in the control group,while the level of motilin and somatostatin were higher than those in the control group,and the differences between the groups were statistically significant(P<0.05);the levels of pepsinogen Ⅰ and pepsinogen Ⅱ in the observation group were higher than those in the control group,and the differences between the groups were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). The Hp eradication rate in the observation group was 97.14% higher than 77.14% in the control group,and the difference was statistically significant(P<0.05). Conclusion The combination of remifentanil and conventional quadruple therapy has a good application effect in patients with CAG caused by Hp infection,which is beneficial for improving gastrointestinal hormone and pepsinogen levels,as well as enhancing Hp eradication rate and treatment safety.